Docetaxel Ethanol-induced Symptoms; The Incidence and Risk Forecating Factor

Ethanol-induced symptoms questionnaire will be administered three times during the baseline visit (Visit 1) - before, during, and within 30 minutes after treatment with docetaxel - and then during the follow-up visit (or phone call) at 24 hours after the treatment. There will be no restrictions as to what concomitant medications can be used before and after treatment with ethanol-containing docetaxel, and investigators will determine the manufacturer, preparation method, and dosage regimen of docetaxel as per routine care at their study site.

The following data will be collected:

• Demographics (gender, age, drinking history)
• Height, body weight and body mass index (BMI)
• Cancer-related data (diagnosis, date of diagnosis)
• ECOG PS
• Underlying diseases
• Prior and concomitant medications
• Data on docetaxel therapy (timing of initiation of the chemotherapy, monotherapy/combination therapy, intervals between chemotherapy treatments, product name, dose (mg), administered ethanol dose (g), blood alcohol content (BAC*), type and volume of intravenous (IV) fluid administered before and after treatment and fluid mixed with docetaxel, duration of injection)

• Blood alcohol content (BAC): Widmark formula = administered ethanol dose (g) / body weight (kg) × gender constant (0.68 for males and 0.55 for females)
• Ethanol-induced symptoms questionnaire

Inclusion criteria

• Subjects who provide written informed consent to collect and use personal information after an explanation of the objectives and methods of the study
• Adult males and females aged 19 years and older
• Chemotherapy with ethanol-containing docetaxel (≥50 mg/m2) alone or in combination for a pathologically confirmed cancer
• ECOG Performance Status (ECOG PS) scores ≤2
• Patients who are capable of understanding the questionnaire items and directly answering questions

Exclusion criteria

• History of psychiatric disorder, seizure, or central nervous system disorder
• Metastasis to the central nervous system (although patients without neurological symptoms are eligible)
• Active hepatitis
• Individuals who meet any of the following:

• AST/ALT ≥2 X upper limit of normal (ULN)
• Total bilirubin ≥2 X ULN
• Hemoglobin <9.0 g/dL
• Combination chemotherapy with ethanol-containing anticancer drugs other than docetaxel
• Alcohol, hypnotic or tranquilizer intake within 24 hours before treatment with docetaxel
• Pregnant or nursing women or women of childbearing potential
• Subjects who are currently participating in another clinical trial (of drugs or medical devices) or plan to do so during the study. However, subjects are allowed to participate in another non-interventional observational study or registry study.
• Patients who are otherwise considered by the investigator to be ineligible for this study